Versor Investments LP Acquires New Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

Versor Investments LP bought a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,400 shares of the company’s stock, valued at approximately $101,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Los Angeles Capital Management LLC purchased a new position in shares of Phathom Pharmaceuticals during the 4th quarter worth approximately $171,000. Bank of New York Mellon Corp grew its holdings in Phathom Pharmaceuticals by 4.6% during the 4th quarter. Bank of New York Mellon Corp now owns 102,748 shares of the company’s stock valued at $834,000 after buying an additional 4,557 shares during the last quarter. Rhumbline Advisers grew its holdings in Phathom Pharmaceuticals by 10.0% during the 4th quarter. Rhumbline Advisers now owns 55,968 shares of the company’s stock valued at $454,000 after buying an additional 5,110 shares during the last quarter. Jennison Associates LLC increased its position in Phathom Pharmaceuticals by 20.4% during the fourth quarter. Jennison Associates LLC now owns 7,062,507 shares of the company’s stock worth $57,348,000 after buying an additional 1,196,118 shares in the last quarter. Finally, Kera Capital Partners Inc. acquired a new position in shares of Phathom Pharmaceuticals in the fourth quarter worth $218,000. Hedge funds and other institutional investors own 99.01% of the company’s stock.

Phathom Pharmaceuticals Trading Up 7.1 %

Phathom Pharmaceuticals stock opened at $5.58 on Wednesday. The stock has a fifty day moving average price of $6.48 and a 200 day moving average price of $11.37. Phathom Pharmaceuticals, Inc. has a 52 week low of $5.07 and a 52 week high of $19.71. The firm has a market capitalization of $381.54 million, a P/E ratio of -0.98 and a beta of 0.54.

Analyst Ratings Changes

PHAT has been the topic of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research note on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th. Finally, Cantor Fitzgerald raised shares of Phathom Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $23.00.

Insider Buying and Selling at Phathom Pharmaceuticals

In related news, insider Terrie Curran sold 19,109 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $125,928.31. Following the sale, the insider now directly owns 360,465 shares of the company’s stock, valued at approximately $2,375,464.35. This trade represents a 5.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Molly Henderson sold 6,583 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $6.59, for a total transaction of $43,381.97. Following the transaction, the chief financial officer now directly owns 93,546 shares of the company’s stock, valued at $616,468.14. This trade represents a 6.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,987 shares of company stock worth $240,551 in the last 90 days. 24.10% of the stock is owned by company insiders.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.